Negative outcome studies in end-stage renal disease

Blood Purification

Volumn 26, Issue 1, 2008, Pages 63-66

  Goldsmith, David ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

Chronic kidney disease; End stage renal disease; Haemodialysis; Outcome study; Randomised controlled trials

Indexed keywords

ALPHA TOCOPHEROL; ATORVASTATIN; CARVEDILOL; CYANOCOBALAMIN; EZETIMIBE PLUS SIMVASTATIN; FOLIC ACID; FOSINOPRIL; HOMOCYSTEINE; IRON; LANTHANUM CARBONATE; MAGNESIUM; PLACEBO; PYRIDOXINE; SEVELAMER; VITAMIN D;

ALLOPATHY; ANEMIA; ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; DIALYSIS; DRUG MEGADOSE; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERPHOSPHATEMIA; HYPERTENSION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MINERAL METABOLISM; MORBIDITY; MORTALITY; PERITONEAL DIALYSIS; POPULATION RESEARCH; PRIORITY JOURNAL; SURVIVAL; TREATMENT OUTCOME; UREMIA; VITAMIN SUPPLEMENTATION;

ANEMIA; ANTIOXIDANTS; CARDIOVASCULAR DISEASES; HUMANS; KIDNEY FAILURE, CHRONIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL DIALYSIS; TREATMENT FAILURE;

EID: 38049054146     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000110567     Document Type: Conference Paper

References (16)

1. Xue JL, Ma JZ, Louis TA, Collins AJ: Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol 2001;12:2753-2758.
2. Kalantar-Zadeh K, Kilpatrick RD, Kuwae N, et al: Reverse epidemiology: a spurious hypothesis or a hardcore reality? Blood Purif 2005;23:57-63.
3. Gotch FA, Sargent JA: A mechanistic analysis of the National Cooperative Dialysis Study (NCDS). Kidney Int 1985;28:526-534.
4. Eknoyan G, Beck GJ, Cheung AK, et al, for the Haemodialysis (HEMO) Study Group: Effect of dialysis dose and membrane flux in maintenance haemodialysis. N Engl J Med 2002;347:2010-2019.
5. Paniagua R, Amato D, Vonesh E, et al: Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized controlled trial. J Am Soc Nephrol 2002;13:1307-1320.
6. Wanner C, Krane V: Lessons learnt from the 4D trial. Nephrol Ther 2006;2:3-7.
7. Agarwal R: Hypertension and survival in chronic haemodialysis patients - past lessons and future opportunities. Kidney Int 2005;67:1-13.
8. Zannad F, Kessler M, Lehert P, et al: Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int 2006;70:1318-1324.
9. Wrone EM, Hornberger JM, Zehnder JL, et al: Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol 2004;15:420-426.
10. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM: Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007;71:438-441.
11. Strippoli GF, Tong A, Palmer SC, Elder G, Craig JC: Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. Cochrane Database Syst Rev 2006;4:CD006254.
12. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-2218.
13. Drueke TB, Locatelli F, Clyne N, et al, CREATE Investigators: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071-2084.
14. Singh AK, Szczech L, Tang KL, et al, CHOIR Investigators: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-2098.
15. Cice G, Ferrara L, D'Andrea A, et al: Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol 2003;41:1438-1444.
16. Boaz M, Smetana S, Weinstein T, et al: Secondary prevention with antioxidants of cardiovascular disease in end-stage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000;356:1213-1218.